Search results
Showing 16 to 23 of 23 results for dupilumab
Dupilumab for children with severe atopic dermatitis [TSID10434]
Topic prioritisation
Dupilumab for treating eosinophilic oesophagitis in children 1 to 11 years [ID6492]
Awaiting development Reference number: GID-TA11383 Expected publication date: TBC
This guideline sets out an antimicrobial prescribing strategy for secondary bacterial infection of eczema and covers infection of other common skin conditions. It aims to optimise antibiotic use and reduce antibiotic resistance. The recommendations are for adults, young people and children aged 72 hours and over. They do not cover diagnosis.
Tralokinumab for treating moderate to severe atopic dermatitis [ID3734]
Discontinued Reference number: GID-TA10596
Upadacitinib for treating moderate to severe atopic dermatitis in people aged 12 and over [ID3733]
Discontinued Reference number: GID-TA10597
Abrocitinib for treating moderate to severe atopic dermatitis in people aged 12 and over [ID3768]
Discontinued Reference number: GID-TA10764
Dupilumab for treating chronic spontaneous urticaria in people 12 years and over [ID4055]
In development Reference number: GID-TA11272 Expected publication date: TBC